Kalshi Launches First Prediction Markets for Phase 3 Drug Trial and FDA Approval Outcomes With AI Firm AppliedXL
Summary
Kalshi launched 13 biotech contracts on July 16 in partnership with AppliedXL, an AI-powered clinical-trial intelligence firm, letting users bet on Phase 3 outcomes and full FDA approval decisions from established biopharma. Named contracts include Gilead's cancer drug approval, AriBio's Alzheimer's trial hitting endpoints and Eli Lilly's retatrutide timing; ~$128K traded in the first hours. Kalshi excludes pediatric and recruiting trials and applies employment-verification insider-trading checks.
Shared on Bluesky by 1 AI expert
-
Yet another Kalshi offering that serves no legitimate economic purpose. It's not possible to make a rational bet on this without material non-public information. It's a market solely for fraud by both regulators and corp…
View on Bluesky →
Originally reported by bloomberg.com
Read the original article →Original headline: Kalshi Launches First Prediction Markets for Phase 3 Drug Trial and FDA Approval Outcomes With AI Firm AppliedXL